Skip to main content
Triangle logo TriangleGet started

BGB-16673 (NCT07508995)

A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL): a one-minute explainerNCT075089951 min

BGB-16673 trial for Chronic Lymphocytic Leukemia (CLL) (NCT07508995). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma that needs treatment. Richter transformation and known central nervous system involvement are excluded.

The idea: combine two oral drugs that interrupt cancer-cell survival. BGB-16673 marks the BTK protein for destruction. Sonrotoclax blocks BCL-2, a protein that prevents programmed cell death. Researchers assess safety and whether sensitive testing can still find leukemia. Some steroid or CD20-antibody treatment is permitted.

This phase 2 study plans 40 patients. Nitin Jain leads at MD Anderson in Houston, the sole recruiting US location.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.